PTPA and sarcoma: Additionally, other studies have demonstrated that inhibiting PP2A enhances the effects of anticancer drugs in resistant cells and increases chemotherapy efficacy, particularly in glioblastoma and sarcoma, emphasizing its broader therapeutic potential [84,85,86].